Table 2. Univariate and multivariate analysis, derivation set.
| Factor | Univariate OR1 (95% CI) | P value | Multivariate OR (95% CI) | P value |
|---|---|---|---|---|
| ECOG | ||||
| 0 | Ref | - | Ref | - |
| 1 | 1.49 (1.18–1.88) | 0.0008 | 1.30 (1.02–1.65) | 0.0315 |
| ≥ 2 | 3.23 (2.07–5.03) | < .0001 | 2.22 (1.40–3.53) | 0.0007 |
| Albumin (g/dL) | ||||
| < 3.5 | 2.22 (1.79–2.74) | < .0001 | 1.59 (1.26–2.00) | < .0001 |
| ≥ 3.5 | Ref | - | Ref | - |
| Alkaline Phosphatase (units/L) | ||||
| ≤ 2.5xULN | Ref | - | Ref | - |
| > 2.5xULN | 2.43 (1.84–3.20) | < .0001 | 1.62 (1.18–2.22) | 0.0026 |
| AST (units/L) | ||||
| ≤ ULN | Ref | - | Ref | - |
| > ULN | 1.69 (1.36–2.10) | < .0001 | 1.39 (1.09–1.77) | 0.0076 |
| Creatinine clearance (mL/min) | ||||
| < 60 | 1.38 (1.03–1.83) | 0.0289 | 1.35 (1.01–1.81) | 0.0455 |
| ≥ 60 | Ref | - | Ref | - |
| Hemoglobin (g/dL) | ||||
| < 10 | 2.79 (2.09–3.72) | < .0001 | 1.99 (1.46–2.71) | < .0001 |
| ≥ 10 | Ref | - | Ref | - |
| Platelets (109/L) | ||||
| < 400 | Ref | - | Ref | - |
| ≥ 400 | 1.80 (1.39–2.35) | < .0001 | 1.30 (0.98–1.72) | 0.0732 |
| Platelets (109/L) | ||||
| < 150 | 1.26 (0.87–1.81) | 0.2790 | NA | NA |
| ≥ 150 | Ref | - | ||
| ALT (units/L) | ||||
| ≤ ULN | Ref | - | NA | NA |
| > ULN | 1.31 (1.03–1.67) | 0.0305 | ||
| WBC (109/L) | ||||
| < 4 | 1.27 (0.82–1.97) | 0.2790 | NA | NA |
| ≥ 4 | Ref | |||
| WBC (109/L) | ||||
| < 10.5 | Ref | - | NA | NA |
| ≥ 10.5 | 1.68 (1.25–2.25) | 0.0005 | ||
| ALC (109/L) | ||||
| < 0.5 | 1.47 (0.99–2.16) | 0.0538 | NA | NA |
| ≥ 0.5 | Ref | - | ||
| Number of Metastatic Sites | ||||
| 0 | Ref | - | NA | NA |
| 1 | 0.66 (0.41–1.04) | 0.0753 | ||
| 2 | 0.62 (0.40–0.98) | 0.0421 | ||
| ≥ 3 | 0.56 (0.37–0.86) | 0.0076 | ||
| Sum. Longest Tumor Dimensions (cm) | ||||
| ≤ 8 | Ref | - | NA | NA |
| > 8 | 1.06 (0.86–1.30) | 0.6121 | ||
| BMI (kg/m2) | ||||
| < 18.5 | 1.59 (0.98–2.60) | - | NA | NA |
| ≥ 18.5 | Ref | 0.0616 | ||
| Primary Site | ||||
| Brain | 1.04 (0.21–5.17) | 0.9669 | NA | NA |
| Breast | 1.07 (0.78–1.49) | 0.7541 | ||
| Gastrointestinal | Ref | - | ||
| Genitourinary | 0.58 (0.40–0.83) | 0.0028 | ||
| Gynecologic | 0.65 (0.45–0.95) | 0.0266 | ||
| Head and neck | 0.68 (0.43– 1.06) | 0.0847 | ||
| Melanoma and skin | 0.74 (0.46–1.19) | 0.2120 | ||
| Sarcoma | 0.68 (0.46–1.01) | 0.0563 | ||
| Thoracic | 0.99 (0.72–1.37) | 0.9729 | ||
| Unknown | 0.83 (0.27–2.52) | 0.7395 | ||
| Pain at Baseline | ||||
| No | Ref | - | NA | NA |
| Yes | 0.72 (0.47–1.10) | 0.1287 | ||
| Prior Lines of Systemic Therapy | ||||
| 0–2 | Ref | - | NA | NA |
| 3 | 1.31 (0.99–1.42) | 0.0554 | ||
| ≥ 4 | 1.36 (1.09–1.69) | 0.0063 |
1
Odd-ratios are for early discontinuation with continuation to cycle 2 as the reference category.